The Italian company Kedrion Biopharma is planning to launch in Tashkent production of a unique medical preparation “Coagulation factor VIII”.
This became known following the negotiations of the representatives of the Italian company with the leadership of the capital's administration.
The parties discussed the prospect of building a production line of the unique medicine used in treating patients with hemophilia. Estimated production cost - $25 million. This amount is planned to be spent not only on production capacity, but also on the laboratory for developing new products.
In the course of the visit, the Italian delegation plans to explore several suitable lands for constructing the plant and signing a co-op memorandum.
For information, Kedrion Biopharma is in the TOP-5 of the world's largest blood plasma. Today, the company's products are represented in more than 100 countries of the world. It has five production platforms.
Within the framework of cooperation, Kedrion can act as a technology partner, transfer a line of drugs, provide the platform with the necessary production technologies, management, control procedures and organize training for employees from the republic at the company's plants.
